Loading…
← CockpitCompetitor Analysis › NAMS NewAmsterdam Pharma Company N.V.Open in the cockpit ↗

NewAmsterdam Pharma Company N.V.NAMSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Clinical-stage biotech developing obicetrapib, an oral CETP inhibitor to lower LDL cholesterol for cardiovascular disease.

Momentum laggard 16
Mkt cap
$2.37B
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$36.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$19.74
1D+1.8%
1W-4.7%
1M-8.2%
3M-28.9%
6M-44.8%
YTD-43.7%
1Y-48.8%
ATR %6.5%
Beta1.40
52w lowhigh53.2% off high

What NewAmsterdam Pharma does

Clinical-stage biotech developing obicetrapib, an oral CETP inhibitor to lower LDL cholesterol for cardiovascular disease.

Has no approved product yet, so it relies on money raised from investors and on a licensing deal with Menarini, which holds the right to sell obicetrapib in Europe once approved and owes milestone and royalty payments back. Late-stage trials, including one on heart-attack and stroke outcomes, are what the value rests on.

Products and services

  • Obicetrapib (LDL-lowering)
  • Combination with ezetimibe

Where it sits in the supply chain

  • Cardiometabolic biopharma
  • CETP-inhibitor drug development
  • Late-stage clinical trials

What could go right

  • Positive outcomes-trial data
  • Oral convenience vs injectable PCSK9 drugs

What could go wrong

  • History of CETP-inhibitor clinical failures industry-wide
  • Large outcomes trial cost/risk

Moat: none (IP / patents). Pre-commercial; must differentiate after past CETP-inhibitor failures at other companies.

Headquarters: Naarden, Netherlands · Founded: 2019 · Employees: 100

Named competitors

NewAmsterdam Pharma at a glance

Size NewAmsterdam Pharma (NAMS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.37B, the 1676th largest of 3,085 United States companies the cockpit tracks. Shares closed at $19.74 on 18 Nov 2026.

Performance Over six months the shares fell 44.8%, against -9.7% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 26.4% over the last twelve months (peer median +4.2%); the operating margin is -900.1% (peer median 11.1%).

Valuation It trades at 67.0× enterprise value to sales against a peer median of 4.2× (most expensive of 20).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 89NAMS 55
Six months, rebased to 100: NewAmsterdam Pharma against the median of its 20 peers (local-currency closes).

NewAmsterdam Pharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$25.9M$22.5M$45.6M$14.1M$103M
Revenue growth—-51%+223%-86%—
Gross profit$25.7M$22.3M$45.5M$14.0M$103M
EBITDA-$233M-$225M-$176M-$181M-$1.31M
Net income-$205M-$204M-$242M-$177M-$22.6M
Free cash flow-$151M-$148M-$159M-$141M$10.4M
Capital expenditure$395,000$246,000$672,000$24,000$221,000
Total debt$76,000$202,000$448,000$60,000$126,000

Quarterly statements and history in the cockpit →

NewAmsterdam Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%0002500013PRGO21623696PBHRGC301080ALM603858301301APLLTD600867600267IDYABIOA-B214450300199NAMS6-month return →1-month return →
Up and to the right = strong over both horizons. NewAmsterdam Pharma is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%0×20×40×60×0002500013PRGO21623696301080ALM301301600867IDYABIOA-B300199H02NAMSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NewAmsterdam Pharma is the large dot.

NewAmsterdam Pharma competitors and peer comparison

Head to head with its named competitors (NAMS vs NOVN.SW vs AMGN vs REGN)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
NewAmsterdam Pharma NAMS$2.37B-45%-26%-900%67.0×n/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Amgen AMGN$240B+34%+9%36%7.2×1.6%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%5.4×-1.1%
Merck & MRK$340B+23%+5%18%5.7×8.3%
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%

How NewAmsterdam Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NewAmsterdam Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureNAMSPeer medianRank in peer set
1-month return-8.2%-4.4%8th lowest of 21
6-month return-44.8%-9.7%3rd lowest of 21
Distance from 52-week high-53.2%-28.5%4th lowest of 21
Revenue growth (TTM)-26.4%+4.2%3rd lowest of 20
Operating margin-900.1%11.1%2nd lowest of 19
EV / Sales67.0×4.2×most expensive of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%67.0×n/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%11.8×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%2.0×47.0%+19.3%
Perrigo PRGOUnited States$2.35B+52%-4%5%1.3×14.1%+0.8%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%16.8×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%13.6×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%3.8×2.3%+2.9%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%14.0×41.3%+27.7%
Almirall ALM.MCSpain$2.46B-13%+24%8%1.9×6.1%+6.5%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%1.5×-2.5%-5.8%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%4.2×3.4%+4.8%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%2.6×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a4.2×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%1.7×-9.7%-1.5%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%48.0×n/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%3.3×n/an/a
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%25.1×25.5%+100.1%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%4.0×-11.0%+37.6%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%12.9×37.4%+6.1%
Haw Par H02.SISingapore$2.08B-25%-13%30%8.4×3.2%+15.7%

Questions

Who are NewAmsterdam Pharma's main competitors?
Named competitors: Novartis (Leqvio) (NOVN.SW), Amgen (Repatha) (AMGN), Regeneron (Praluent) (REGN), Esperion Therapeutics (private or unlisted), Merck (MRK), AstraZeneca (AZN.L). The cockpit's measured peer set (industry) also includes Sam Chun Dang Pharm (000250.KS), HUTCHMED (China) (0013.HK), Perrigo (PRGO), Keymed Biosciences (2162.HK), InSilico Medicine Cayman TopCo (3696.HK), Prestige Consumer Healthcare (PBH).
Is NewAmsterdam Pharma expensive compared with its peers?
On ev / sales it trades at 67.0× against a peer median of 4.2×, most expensive of 20 in its peer set.
How has NewAmsterdam Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -44.8% against -9.7% for the median peer; over one year -48.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.